Cumberland Partners Ltd Raises Holdings in AbbVie Inc. $ABBV

Cumberland Partners Ltd increased its stake in shares of AbbVie Inc. (NYSE:ABBV) by 82.9% in the 2nd quarter, HoldingsChannel reports. The firm owned 46,647 shares of the company’s stock after buying an additional 21,140 shares during the quarter. Cumberland Partners Ltd’s holdings in AbbVie were worth $11,738,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Litman Gregory Wealth Management LLC purchased a new stake in shares of AbbVie in the fourth quarter valued at $28,000. Imprint Wealth LLC raised its stake in AbbVie by 56.2% in the 4th quarter. Imprint Wealth LLC now owns 125 shares of the company’s stock valued at $29,000 after purchasing an additional 45 shares during the last quarter. Legacy Wealth Managment LLC ID lifted its holdings in AbbVie by 115.9% in the 4th quarter. Legacy Wealth Managment LLC ID now owns 136 shares of the company’s stock valued at $31,000 after purchasing an additional 73 shares in the last quarter. IFC & Insurance Marketing Inc. acquired a new stake in shares of AbbVie during the 4th quarter worth about $31,000. Finally, Abound Financial LLC acquired a new stake in shares of AbbVie during the 4th quarter worth about $32,000. Hedge funds and other institutional investors own 70.23% of the company’s stock.

Analyst Ratings Changes

A number of analysts recently issued reports on the stock. Royal Bank Of Canada raised their target price on shares of AbbVie from $260.00 to $280.00 and gave the stock an “outperform” rating in a research report on Friday, July 10th. Wells Fargo & Company increased their price target on AbbVie from $295.00 to $300.00 and gave the stock an “overweight” rating in a research note on Monday, August 17th. DZ Bank raised AbbVie from a “hold” rating to a “strong-buy” rating in a research report on Thursday, April 30th. Sanford C. Bernstein reiterated a “market perform” rating on shares of AbbVie in a research report on Tuesday, June 23rd. Finally, UBS Group raised their price target on AbbVie from $230.00 to $260.00 and gave the stock a “neutral” rating in a research note on Monday, July 13th. Two investment analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating and five have issued a Hold rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $275.95.

Insider Buying and Selling at AbbVie

In related news, EVP Nicholas Donoghoe sold 32,710 shares of the stock in a transaction on Friday, August 14th. The stock was sold at an average price of $250.00, for a total value of $8,177,500.00. Following the completion of the transaction, the executive vice president owned 74,430 shares in the company, valued at $18,607,500. This trade represents a 30.53% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Company insiders own 0.06% of the company’s stock.

More AbbVie News

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie’s Humira replacement strategy is gaining credibility: second-quarter revenue rose 10.2% to $16.99 billion, led by immunology products and supported by neuroscience. This suggests Skyrizi, Rinvoq and other newer medicines are more than offsetting Humira’s biosimilar-related decline. AbbVie’s Humira Replacement Strategy Is Working
• Positive Sentiment: New lung-cancer data for investigational treatments ABBV-1480, ABBV-706 and Temab-A point to potentially meaningful future growth in oncology. Reported response rates and manageable safety profiles strengthen the case for AbbVie’s longer-term pipeline, though the programs remain dependent on additional clinical results and approvals. Is AbbVie Quietly Rebalancing Its Growth Story Around Oncology Innovation?
• Positive Sentiment: Several investment managers increased their AbbVie holdings, including Convergence Financial, which nearly doubled its position, and Donaldson Capital Management, which modestly raised its stake. These filings provide a supportive institutional signal but are not major earnings catalysts. Convergence Financial Increased Its AbbVie Holdings
• Neutral Sentiment: In comparisons with Eli Lilly, AbbVie offers a more established cash-generating portfolio and attractive pipeline opportunities, while Lilly has stronger headline growth prospects. The debate highlights AbbVie’s balance between income, stability and pipeline execution rather than a clear near-term catalyst. LLY vs. ABBV: Which Stock Has the Stronger Growth Prospects?
• Negative Sentiment: Second-quarter oncology sales declined 2.4% as Imbruvica continued to weaken. Growth from Venclexta and newer medicines partly offset the pressure, but the result underscores ongoing reliance on successful launches and pipeline products to revive the franchise. How Did AbbVie’s Oncology Sales Hold Up in Q2?

AbbVie Price Performance

Shares of ABBV stock opened at $265.56 on Wednesday. AbbVie Inc. has a 12 month low of $190.75 and a 12 month high of $267.47. The firm has a market capitalization of $469.18 billion, a P/E ratio of 75.02, a P/E/G ratio of 0.88 and a beta of 0.30. The company’s fifty day moving average price is $250.20 and its two-hundred day moving average price is $228.12.

AbbVie (NYSE:ABBV) last announced its quarterly earnings data on Friday, July 31st. The company reported $3.65 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.61 by $0.04. The firm had revenue of $16.99 billion for the quarter, compared to analysts’ expectations of $16.80 billion. AbbVie had a negative return on equity of 422.07% and a net margin of 9.80%.AbbVie’s revenue for the quarter was up 10.2% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $2.97 earnings per share. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. On average, sell-side analysts anticipate that AbbVie Inc. will post 14.06 EPS for the current year.

AbbVie Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Friday, August 14th. Stockholders of record on Wednesday, July 15th were issued a $1.73 dividend. The ex-dividend date was Wednesday, July 15th. This represents a $6.92 annualized dividend and a dividend yield of 2.6%. AbbVie’s dividend payout ratio is 195.48%.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.